Bioventus
Durham · Founded 2012
About Bioventus
Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles. Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the leading distributors of osteoarthritis joint fluid therapies. Key products include: - EXOGEN(r) Ultrasound Bone Healing System - SUPARTZ(r) Joint Fluid Therapy (US only) - DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only) Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide. Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.
Company Facts
- Founded: 2012
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $500K – $1M
- Total funding: $827.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jul 2025)
- Ticker: nasdaq:BVS
- Website: bioventus.com
- Phone: (919) 474-6700
Industries & Categories
Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/bioventus-16896 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.